Home-Based Corrective Exercise With Remote Reinforcement for Upper Crossed Syndrome
NCT07924995, Not applicable, Not yet recruiting, Cardenal Herrera University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Home-Based Corrective Exercise With Remote Reinforcement for Upper Crossed Syndrome | ClinicalTrials.gov |
| NCT number | NCT07924995 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 96 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Cardenal Herrera University | ClinicalTrials.gov |
| Conditions | Upper Cross Syndrome, Forward Head Posture, Rounded Shoulder Posture, Thoracic Hyperkyphosis, Musculoskeletal Diseases | ClinicalTrials.gov |
| Interventions | Home-based corrective exercise program with incentive spirometer and remote reinforcement, Home-based corrective exercise program (no spirometer, minimal follow-up) | ClinicalTrials.gov |
| First posted | 2026-11-09 | ClinicalTrials.gov |
| Last updated | 2026-11-09 | ClinicalTrials.gov |
Registered outcomes 11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Craniovertebral Angle (CVA) | Baseline (Week 0), Week 4, Week 8, Week 12 | Angle formed between the horizontal line at the C7 spinous process and the line connecting C7 to the ipsilateral ear tragus, measured by lateral photogrammetry using standardized adhesive markers and Kinovea software. A lower CVA indicates greater forward head posture (normal \> 52°). | ClinicalTrials.gov |
| Secondary | Rounded Shoulder Posture Angle (RSP) | Baseline (Week 0), Week 4, Week 8, Week 12 | Angle between the line connecting the C7 spinous process to the right acromion and the horizontal, measured by lateral photogrammetry (Kinovea). Values \> 52° indicate rounded shoulder posture. | ClinicalTrials.gov |
| Secondary | Thoracic Kyphosis Angle - Bubble Inclinometer | Baseline (Week 0), Week 4, Week 8, Week 12 | Single-inclinometer sequential method: the instrument (Baseline, Fabrication Enterprises Inc., White Plains, NY) is zeroed at T1 and the angle is read at T12. Three measurements per time point; mean used for analysis. | ClinicalTrials.gov |
| Secondary | Thoracic Kyphosis Angle - Smartphone Inclinometer | Baseline (Week 0), Week 4, Week 8, Week 12 | Same T1-T12 sequential method using the Clinometer app (Plaincode) on iPhone 17. The upper corner of the narrow side of the phone is placed at T1 (zeroed to 0°), then moved to T12 (angle read). Three measurements per time point; mean used for analysis. | ClinicalTrials.gov |
| Secondary | Pain Intensity - Visual Analogue Scale (VAS) | Baseline (Week 0), Week 4, Week 8, Week 12 | 100-mm horizontal VAS (0 = no pain; 100 = worst imaginable pain) for neck and interscapular pain during the past week. Minimum clinically important difference (MCID): 15 mm. | ClinicalTrials.gov |
| Secondary | Cervical Disability - Neck Disability Index (NDI) | Baseline (Week 0), Week 4, Week 8, Week 12 | 10-item self-reported questionnaire assessing the impact of neck pain on daily activities; total score 0-50. Spanish validated version used. MCID: 5 points (10%). Interpretation: 0-8% no disability; 10-28% mild; 30-48% moderate; 50-64% severe; ≥ 64% complete disability. | ClinicalTrials.gov |
| Secondary | Shoulder Pain and Disability - SPADI | Baseline (Week 0), Week 4, Week 8, Week 12 | 13-item self-reported questionnaire with two subscales (Pain: 5 items; Disability: 8 items), each item scored 0-10. Total score 0-100 (higher = worse). MCID: 13-18 points. Spanish validated version used. | ClinicalTrials.gov |
| Secondary | Exercise Adherence | Weeks 1-12 (cumulative at each assessment point) | Percentage of prescribed sessions completed out of 36 planned sessions (3/week × 12 weeks), recorded in standardized session diaries. Adequate adherence defined as ≥ 70% | ClinicalTrials.gov |
| Secondary | Forced Vital Capacity (FVC, % predicted) | Baseline (Week 0), Week 12 | Spirometric measurement (forced vital capacity as percentage of age-sex-height-weight predicted value). ATS acceptability and reproducibility criteria applied; 3 measurements per session, mean used. | ClinicalTrials.gov |
| Secondary | FEV₁/FVC Ratio (% predicted) | Baseline (Week 0), Week 12 | Ratio of forced expiratory volume in 1 second to forced vital capacity, expressed as percentage of predicted value. | ClinicalTrials.gov |
| Secondary | Maximum Voluntary Ventilation (MVV, % predicted) | Baseline (Week 0), Week 12 | Spirometric measure of maximum airflow over 12-15 seconds, expressed as percentage of predicted value. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 5
The papers the trial lists on ClinicalTrials.gov.
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)